Compare NBIX & MAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | MAA |
|---|---|---|
| Founded | 1992 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.8B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | MAA |
|---|---|---|
| Price | $130.61 | $126.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 18 |
| Target Price | ★ $180.82 | $147.94 |
| AVG Volume (30 Days) | ★ 901.1K | 767.4K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 4.86% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $22.85 | $2.67 |
| Revenue Next Year | $10.36 | $2.91 |
| P/E Ratio | ★ $27.09 | $35.71 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $97.30 | $120.30 |
| 52 Week High | $160.18 | $169.00 |
| Indicator | NBIX | MAA |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 51.36 |
| Support Level | $124.29 | $125.75 |
| Resistance Level | $136.23 | $136.72 |
| Average True Range (ATR) | 4.29 | 1.87 |
| MACD | -0.08 | 0.78 |
| Stochastic Oscillator | 59.64 | 87.67 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Mid-America Apartment Communities Inc is a multifamily-focused, self-administered and self-managed real estate investment trust. The company owns, operates, acquires and selectively develops apartment communities located in the Southeast, Southwest and Mid-Atlantic regions of the U.S. Its business objectives are to generate a sustainable, stable and increasing cash flow that will fund its dividends and distributions through all parts of the real estate investment cycle. It operates in two segments, Same Store and Non-Same Store and Other. The majority of the revenue is derived from Same Store segment.